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Purpose  We have developed a 186Re-MAG3 complex-conjugated 
bisphosphonate (186Re-MAG3-HBP) for the treatment of painful bone 
metastases. We assumed competitive inhibitors of protein binding to be 
useful for procuring a favorable biodistribution of 186Re-MAG3-HBP for 
the palliation of bone pain because it has been reported that the concurrent 
administration of 99mTc-MAG3 and drugs with high affinity for serum 
protein produced competitive displacement at specific binding sites and 
enhanced total clearance and tissue distribution.  
Methods  The displacement effects of several protein-binding inhibitors 
on the protein binding of 186Re-MAG3-HBP were investigated. 
Biodistribution experiments were performed by intravenously 
administering 186Re-MAG3-HBP into rats with ceftriaxone as a competitive 
protein-binding inhibitor or saline. 
Results  The protein binding of 186Re-MAG3-HBP in rat serum, human 
serum, and a human serum albumin solution was significantly decreased by 
the addition of ceftriaxone, which has high affinity for binding site I on 
serum albumin. In the biodistribution experiments, pretreatment with 
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ceftriaxone enhanced the clearance of the radioactivity of 
186Re-MAG3-HBP in blood and nontarget tissues but had no effect on 
accumulation in bone. 
Conclusions  The findings suggested that the use of protein-binding 
competitive inhibitors would be effective in improving the 
pharmacokinetics of radiopharmaceuticals with high affinity for serum 
protein. 
 
Keywords: protein binding, absorbed radiation dose, palliation, 
bisphosphonate, rhenium-186 
 




      Bone metastases often present with severe bone pain, which has a 
significant impact on patients’ quality of life [1]. Systemic radionuclide 
therapy using specifically localized bone-seeking radiopharmaceuticals is 
preferable because of the few side effects and long-lasting therapeutic 
effects brought about by a single injection [2]. Previously, based on the 
concept of bifunctional radiopharmaceuticals, we have developed 186Re 
complex-conjugated bisphosphonate analogs for the palliation of painful 
bone metastases, and have demonstrated the utility of these compounds 
[3-7]. Among these compounds, 186Re-mercaptoacetylglycylglycylglycine 
(MAG3) complex-conjugated bisphosphonate, 
[[[[(4-hydroxy-4,4-diphosphonobutyl)carbamoylmethyl]carbamoylmethyl]
carbamoylmethyl]carbamoylmethanethiolate] oxorhenium(V) 
(186Re-MAG3-HBP) showed superior biodistribution characteristics as a 
therapeutic agent for the palliation of painful bone metastases [3]. However, 
186Re-MAG3-HBP may have high affinity for serum protein because 
99mTc-MAG3-HBP had a high rate of binding to serum protein, which might 
be attributed to the high protein-binding ratio of the 99mTc-MAG3 complex 
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[8-10]. We synthesized a 99mTc-6-hydrazinopyridine-3-carboxylic 
acid-conjugated bisphosphonate (99mTc-HYNIC-HBP), which had a lower 
protein-binding ratio and improved biodistribution compared with that of 
99mTc-MAG3-HBP [11]. However, since HYNIC cannot form a stable 
complex with 186Re, in this study we tried a different approach to reducing 
the protein binding. 
      The binding of drugs to serum proteins has important 
pharmacokinetic consequences because it influences their distribution, 
metabolism, and excretion. Many of the interactions occur in relatively 
well-defined regions on human serum albumin (HSA) and on α1-acid 
glycoprotein (AGP). Sudlow et al. reported the presence of two primary 
drug-binding sites on HSA, namely site I (also referred to as the warfarin 
binding site) and site II (the indole-benzodiazepine binding site) [12,13]. 
As a result, coadministration of drugs with high protein-binding affinity 
might produce competitive displacement at the binding site or might 
influence the simultaneous binding of another drug by electrostatic effects 
and/or binding-induced conformational changes in the protein, causing 
higher free concentrations of drugs in plasma than with the administration 
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of the drugs alone [14-17]. Kawai et al. applied a strategy for the 
competitive displacement of protein bindings to radiopharmaceuticals for 
the first time, and reported that treatment of a drug with high protein 
binding affinity increased the free fraction of 99mTc-MAG3, achieving rapid 
accumulation in the kidney and fast clearance from the blood [18].  
      In this study, the displacement effects of several drugs with high 
affinity for HSA binding site I and site II on 186Re-MAG3-HBP were 
evaluated in vitro. Biodistribution experiments of 186Re-MAG3-HBP with 
or without pretreatment with an inhibitor were performed to investigate the 
validity of employing a competitive inhibitor of protein binding. 
 
Materials and methods 
Materials 
      186Re was supplied by the Japan Atomic Energy Agency 
(Tokai-mura, Japan) as 186ReO4- [19]. 186Re-MAG3-HBP and 
nonradioactive Re-MAG3 were synthesized as described previously [3]. 
HSA (essentially fatty acid free albumin), AGP, ceftriaxone, and cefazolin 
were purchased from Sigma Chemical Co. (St. Louis, MO). Bucolome 
 




Pharmaceutical Co., Ltd., Tokyo, Japan) was obtained as a pure substance 
from the manufacturer. Ibuprofen was purchased from Nakalai Tesque, Inc. 
(Kyoto, Japan). Other reagents were of reagent grade and used as received. 
 
In vitro protein-binding studies 
      The protein-binding ratios of 186Re-MAG3-HBP were evaluated by 
ultrafiltration (Centrifree; Millipore, Billerica, MA). 186Re-MAG3-HBP (74 
kBq in 33.3 μL saline) was added to 300 μL of rat or human serum (or HSA, 
AGP solution). Mixtures (280 μL) of 186Re-MAG3-HBP and serum were 
centrifuged at 1,000g for 20 min at room temperature. The radioactivity of 
the part of the initial solutions (30 μL) and the filtrates (30 μL) was 
measured with an auto well gamma counter (ARC-2000; Aloka, Tokyo, 
Japan). The free fraction and protein-binding ratio were determined as 
follows: 
Free fraction (%) = (radioactivity of filtrate) / (radioactivity of initial 
solution) × 100.  
Protein-binding ratio (%) = 100 – (Free fraction).  
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The HSA (740 μM) and AGP (17 μM) solutions were prepared at normal 
human serum concentrations. 
      In order to investigate the moiety with high affinity for HSA in 
186Re-MAG3-HBP, nonradioactive Re-MAG3 and bisphosphonate 
(1-hydroxyethylidene-1,1-diphosphonate; HEDP) at concentrations of 0.4 
mM, 1 mM, or 2.5 mM were added to mixtures of 186Re-MAG3-HBP and 
HSA. Then, the protein-binding ratios of 186Re-MAG3-HBP were evaluated 
as described above. 
      The effects of each competitive protein-binding inhibitor were 
examined in rat serum, human serum, and HSA solution. Bucolome [20,21], 
ceftriaxone [22], and cefazolin [23] as displacers of HSA binding site I, and 
ibuprofen [13] as a displacer of HSA binding site II were added to each 
serum at 400μM before the addition of 186Re-MAG3-HBP. Then, the 
protein binding of 186Re-MAG3-HBP was evaluated as described above. 
 
In vivo studies 
      Animal experiments were conducted in accordance with our 
institutional guidelines; the experimental procedures were approved by the 
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Kyoto University Animal Care Committee. Biodistribution experiments 
were performed by intravenous injection of 250 μL of the diluted tracer 
solution into male Wistar rats (190-230 g, Japan SLC, Inc., Hamamatsu, 
Japan). Ceftriaxone (50 mg/kg), as a competitive protein-binding inhibitor, 
was administered intravenously just before the tracer was injected. Saline 
was administered to the rats in a control group instead of ceftriaxone. 
Groups of four or five rats each were sacrificed by decapitation at 5, 10, 30, 
60, and 180 minutes postinjection. Tissues of interest were removed and 
weighed. The entire left femur was isolated as a representative bone sample. 
The levels of radioactivity in the tissues were determined with an auto well 
gamma counter and corrected for background radiation and physical decay 
during counting. 
      To determine detailed blood time-activity curves, blood samples of 
the male Wistar rats (190-230 g) were taken. Specifically, a polyethylene 
cannula (i.d. 0.5 mm, o.d. 0.8 mm; Dural Plastics, Dural, Australia) filled 
with heparin in saline was inserted into the femoral artery of each rat 
anesthetized with sodium pentobarbital. After intravenous injections via the 
tail of the tracer and ceftriaxone (50 mg/kg) or saline, blood samples were 
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taken at 2, 5, 7, 10, 15, 20, 30, 40, 50, and 60 min postinjection. Blood 
samples were weighed and the radioactivity was determined with an auto 
well gamma counter. The area under the blood time-activity curve was 
calculated by numeral integration using a linear trapezoidal formula from 
the time of tracer injection to the time of last blood sampling and 
extrapolation to infinity based on a monoexponential equation [24].  
 
Radiation Dose Estimates 
      For estimation of the radiation dose absorbed by the bone and bone 
marrow, the level of activity in the bone marrow was assumed to be 30% of 
that in the blood [25]. Red marrow mass was assumed to be 25% of blood 
volume [25]. Blood volume was calculated using the following formula 
[26]. 
Blood volume (mL) = 0.06 × body weight (g) + 0.77 
The bone mass of the rats was assumed to be 10% of body weight [27]. 
According to the International Commission on Radiological Protection 
(ICRP), an equal distribution of the radionuclide to trabecular and cortical 
bone was assumed [28]. The no decay-corrected activity from each source 
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organ was converted to a percentage of the injected dose (ID). A 
time-activity curve was created for each organ by plotting the percentage of 
ID versus time. The area under an organ’s activity curve from time zero to 
infinity was calculated by the above-mentioned method. According to the 
values, absorbed radiation doses were calculated for an adult patient using 
OLINDA 1.0 software (Vanderbilt University) [29]. 
 
Statistical Analysis 
      An unpaired Students’ t test was used for the biodistribution 
experiments. A one-way analysis of variance (ANOVA) followed by 
Dunnett’s post hoc test compared to the control group was used for in vitro 
protein-binding experiments. Results were considered statistically 
significant at p < 0.05. 
 
Results 
Binding of 186Re-MAG3-HBP to serum protein 
      The percentages of 186Re-MAG3-HBP bound to rat serum and 
human serum were 97.4 ± 1.1% and 97.0 ± 0.3%, respectively. In the case 
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of the purified human serum proteins, 186Re-MAG3-HBP bound to HSA 
strongly (98.2 ± 0.1%) and bound to AGP weakly (11.0 ± 0.5%). 
      In the experiments in which nonradioactive Re-MAG3 or HEDP 
was added to a mixture of 186Re-MAG3-HBP with HSA, Re-MAG3 
appreciably inhibited the binding of 186Re-MAG3-HBP to HSA on a 
dose-dependent basis (Fig. 1). 
 
Effects of several drugs on the binding of 186Re-MAG3-HBP to serum 
protein 
      The effects of several drugs as competitive inhibitors on serum 
protein binding of 186Re-MAG3-HBP were evaluated. Data was expressed 
relative to the free fraction value for the control group (without inhibitor). 
On the addition of bucolome or ceftriaxone, the free fraction of 
186Re-MAG3-HBP in rat serum increased significantly compared with that 
of the control (Fig. 2a). In human serum, the addition of ceftriaxone 
significantly increased the free fraction of 186Re-MAG3-HBP (Fig. 2b). In 
HSA solution, the addition of bucolome, ceftriaxone, cefazolin, or 
ibuprofen significantly increased the free fraction of 186Re-MAG3-HBP 
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(Fig. 2c). The increase on the addition of bucolome, ceftriaxone, or 
cefazolin was more remarkable than that on the addition of ibuprofen 
(significance difference determined with the Tukey-Kramer test). 
 
In vivo studies 
      Table 1 lists the biodistribution of 186Re-MAG3-HBP with or 
without pretreatment with ceftriaxone in normal rats, expressed as a 
percentage of the injected dose per gram tissue (%ID/g). As to the 
accumulation of radioactivity in the target tissue, bone, there was no 
difference between the ceftriaxone-pretreated group and the control group. 
At the same time, the pretreated group had lower levels of radioactivity 
than did the control group in nontarget tissues such as kidney. 
      The blood time-activity curves of 186Re-MAG3-HBP with or 
without pretreatment with ceftriaxone in rats, expressed as %ID/g, are 
presented in Figure 3. The clearance value in the ceftriaxone-pretreated 
group and the control group calculated from the area under the curve was 
172.3 ± 11.8 and 115.8 ± 14.4 mL/h, respectively. 
 
 




      Table 2 lists the estimated absorbed radiation doses for 
186Re-MAG3-HBP with and without pretreatment with ceftriaxone. We 
assumed that the radiation dose absorbed by the osteogenic cells is an index 
of the therapeutic effects. There was no difference in the absorbed radiation 
dose versus that without the ceftriaxone. Although the dose absorbed by red 
marrow, a dose-limiting factor of bone-seeking radiopharmaceuticals, did 
not differ between the two groups, that absorbed by other nontarget tissues 
such as kidney was markedly decreased by pretreatment with ceftriaxone. 
 
Discussion 
      In the protein-binding experiments in vitro, 186Re-MAG3-HBP 
showed very high ratios of protein binding in human and rat serum. These 
high ratios of protein binding are probably due to the strong binding of 
186Re-MAG3-HBP to serum albumin because 186Re-MAG3-HBP exhibited 
extensive binding to HSA and little binding to AGP. In experiments using 
several inhibitors of protein binding, the HSA site I inhibitors were more 
effective than the HSA site II inhibitor. A previous study showed that 
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99mTc-MAG3 binds specifically with binding site I on HSA [18]. If the 
186Re-MAG3 structure contributes to the binding of 186Re-MAG3-HBP, the 
result of the experiments using an inhibitor could be reasonable. Then, to 
investigate the moiety with high affinity for HSA in 186Re-MAG3-HBP, the 
binding to HSA was examined when a large excess of nonradioactive 
Re-MAG3 or bisphosphonate (HEDP) was added to a mixture of 
186Re-MAG3-HBP and HSA. As a result, the addition of Re-MAG3 
strongly inhibited the binding of 186Re-MAG3-HBP to HSA, indicating that 
the binding of 186Re-MAG3-HBP was attributable to the 186Re-MAG3 
moiety. 
      Ceftriaxone was the most effective of the HSA site I inhibitors used 
in this study. At the same time, we consider ceftriaxone, one of the 
antibiotics, to be effective for clinical applications because it can be 
administered clinically at a comparable dose from the point of view of 
safety. Previously, Haradahira et al. reported that the uptake in the brain of 
a radioligand for the glycine binding site of the NMDA receptor, 
[11C]L-703,717, was increased by the use of warfarin, which inhibits 
plasma protein binding in mice [30]. The strategy is similar to that of our 
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study, but the injected dose of warfarin in that study was quite different 
from a clinical dose. In this study, in vitro experiments were performed 
under conditions where the final concentration of inhibitors was 360 μM. It 
was reported that the early plasma concentration of ceftriaxone was over 
400 μM after a single intravenous administration of 2 g of ceftriaxone to an 
adult [31]. The administration of 2 g of ceftriaxone as a clinically available 
dose should be useful for the competitive inhibition of protein binding 
because ceftriaxone significantly elevated the free fraction of 
186Re-MAG3-HBP at the lower concentration in vitro. Another advantage 
of ceftriaxone is its long elimination half-life (6 to 9 h) [31,32]. 
Maintaining a high concentration in blood seems to be favorable for 
competitive inhibition at serum-binding sites. Thus, in vivo experiments 
were performed with pretreatment of ceftriaxone as an inhibitor of protein 
binding. As expected, the clearance from blood of 186Re-MAG3-HBP was 
greater with the pretreatment than without. These results suggest that 
ceftriaxone could be also useful in vivo as a competitive protein-binding 
inhibitor. Furthermore, the ceftriaxone-pretreated group also showed lower 
radioactivity levels than did the control group in nontarget tissues, such as 
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kidney. These decreases in radioactivity might be attributed to an enhanced 
distribution to the tissues with the decrease in protein binding. However, 
there was no significant change between the groups in the accumulation in 
bone. We suppose that it is the reason that 186Re-MAG3-HBP binds to the 
hydroxyapatite in bone and is retained for a long term without excretion. 
Accordingly, pretreatment with ceftriaxone could be useful for improving 
the biodistribution of 186Re-MAG3-HBP from the point of view of 
decreasing the radiation dose to nontarget tissues. The results from the 
estimates of absorbed doses indicate that the dose absorbed by the kidney 
was certainly decreased and that absorbed by osteogenic cells was almost 
the same. We assumed that the dose of radiation absorbed by the 
osteogenic cells is an index of the therapeutic effects. Although osteogenic 
cells should not be the exact target of this type of internal radionuclide 
therapy, we cannot describe a direct index of the therapeutic effect because 
we used normal rats and calculated the radiation dose to normal humans by 
extrapolation. The therapeutic (palliation) effects must occur by binding 
radiopharmaceuticals with hydroxyapatite in or near metastatic bone. 
Because the accumulations of radiopharmaceuticals in metastatic bone are 
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not specific, it is predicted that the radiation dose of osteogenic cells would 
correlate with the therapeutic effect. The results of radiation dose indicate 
that it could decrease toxicity to kidney tissue while obtaining the same 
therapeutic effect. However, when the usual therapeutic dose of 
186Re-MAG3-HBP is injected, the strategy might have little clinical merit 
because the initial radiation dose to the kidneys is not very high. For 
example, when a much higher dose was injected with an autologous 
peripheral blood stem cell transplant [33,34], the strategy should be more 
effective. At the same time, the dose absorbed by red marrow, which is 
known as a dose-limiting factor of bone-seeking radiopharmaceuticals, was 
not decreased. Since almost the entire dose absorbed by red marrow is from 
the radioactivity accumulated in bone, accelerated blood clearance would 
not affect the absorbed dose in red marrow. 
      In conclusion, pretreatment with ceftriaxone enhanced the clearance 
of the radioactivity of 186Re-MAG3-HBP in blood and nontarget tissues 
although it had no effect on accumulations in bone. These findings 
suggested that treatment with a protein-binding competitive inhibitor would 
be effective for radiopharmaceuticals with high affinity for serum protein to 
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improve their pharmacokinetics, and this strategy might have even greater 
effects for other radiopharmaceuticals. 
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Fig. 1. Displacement of 186Re-MAG3-HBP from protein in HSA. 
Re-MAG3 and HEDP were loaded at 0.4 mM, 1 mM, and 2.5 mM (final 
concentration). Data are expressed relative to the free fraction for the 
control group (mean ± SD for three experiments). Significant differences 
from control (without inhibitor) were identified with Dunnett's test (*p < 
0.05, **p < 0.01) 
 
Fig. 2. Displacement of 186Re-MAG3-HBP from protein in a rat serum, b 
human serum, and c HSA. Each competitive protein-binding inhibitor was 
loaded at a final concentration of 400 μM. Data are expressed relative to 
the free fraction for the control group (mean ± SD for three experiments). 
Significant differences from control (without inhibitor) were identified with 
Dunnett's test (*p < 0.05, **p < 0.01). 
 
Fig. 3. Radioactivity in blood after injection of 186Re-MAG3-HBP in rats. 
Ceftriaxone (open circles) (50 mg/kg) or saline (closed circles) as a control 
was loaded just before 186Re-MAG3-HBP was injected. Data are expressed 
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as a percentage of the injected dose per gram (mean ± SD for seven rats) on 
a log scale. 
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Table 1. Biodistribution of radioactivity after intravenous administration of 
186Re-MAG3-HBP with or without pretreatment with ceftriaxone in rats. 
 Time after administration 
Tissue 5 min 10 min 30 min 60 min 180 min 
Pretreatment of ceftriaxone 
Blood 0.98** 0.57 0.19* 0.05** 0.02** 
 (0.19) (0.06) (0.02) (0.00) (0.00) 
Liver 0.32** 0.13 0.08** 0.07** 0.06* 
 (0.03) (0.01) (0.00) (0.01) (0.01) 
Kidney 2.76 1.22 0.85** 0.62** 0.58 
 (1.15) (0.13) (0.02) (0.06) (0.10) 
Intestine 0.17* 0.09 0.08 0.14 0.26 
 (0.03) (0.01) (0.02) (0.04) (0.10) 
Spleen 0.27 0.12 0.06* 0.05 0.05 
 (0.03) (0.05) (0.01) (0.01) (0.01) 
Femur 1.73 1.88 3.47 3.89 4.01 
 (0.20) (0.08) (0.14) (0.24) (0.28) 
Muscle 0.15 0.12 0.06 0.01 0.01 
 (0.02) (0.06) (0.01) (0.00) (0.01) 
 
Control 
Blood 1.32 0.77 0.27 0.07 0.03 
 (0.10) (0.22) (0.06) (0.01) (0.00) 
Liver 0.44 0.16 0.09 0.07 0.08 
 (0.06) (0.04) (0.00) (0.00) (0.01) 
Kidney 4.35 1.56 1.40 0.85 0.73 
 (2.40) (0.38) (0.08) (0.11) (0.14) 
Intestine 0.25 0.10 0.10 0.11 0.30 
 (0.07) (0.03) (0.02) (0.02) (0.16) 
Spleen 0.28 0.15 0.08 0.05 0.04 
 (0.02) (0.03) (0.01) (0.00) (0.01) 
Femur 1.67 1.91 3.43 4.15 4.14 
 (0.22) (0.10) (0.33) (0.14) (0.65) 
Muscle 0.17 0.11 0.06 0.01 0.02 
 (0.02) (0.01) (0.02) (0.01) (0.02) 
Each value represents the mean (SD) for four to five rats. 
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Expressed as % of injected dose per gram. 
Significance determined by Students’ t test; * p < 0.05, ** p < 0.01.
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Table 2. Absorbed dose estimates of 186Re-MAG3-HBP with or without 
pretreatment with ceftriaxone. 
Organ Pretreatment with 
ceftriaxone 
Control 
Osteogenic cellsa 8.75 8.87 
Red marrowa 3.01 3.05 
Livera 0.03 0.04 
Kidneysa 0.42 0.77 
Small intestinea 0.01 0.01 
Spleena 0.02 0.03 
Effective dose equivalentb 0.69 0.72 
Effective doseb 0.50 0.51 
a Expressed as mGy/MBq. 
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FIGURE 2. 
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